Former Merck dealmaker takes aim at colon germ

June 6, 2014 4:50 PM

17 0

(Reuters) - An infectious disease expert and former head dealmaker at Merck & Co is racing against his ex-employer and other drugmakers to develop a treatment for a germ that ravages the colon and kills as many as 14,000 Americans each year.

Roger Pomerantz on Monday became chief executive officer of privately held Seres Health, whose lead product has proven highly effective against the c. difficile bacteria in early-stage clinical trials.

Read more

To category page